193
Participants
Start Date
September 26, 2018
Primary Completion Date
August 13, 2020
Study Completion Date
August 13, 2020
Ticagrelor
"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day."
Placebo
"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
Research Site, Ho
Research Site, Accra
Research Site, Tripoli
Research Site, Brussels
Research Site, Kumasi
Research Site, Soweto
Research Site, Mbeya
Research Site, Edegem
Research Site, Antalya
Research Site, Cape Town
Research Site, Kampala
Research Site, Brooklyn
Research Site, Cairo
Research Site, Athens
Research Site, Cairo
Research Site, Cairo
Research Site, Alexandria
Research Site, Madrid
Research Site, Madrid
Research Site, Charleston
Research Site, Miami
Research Site, Fort Lauderdale
Research Site, Mersin
Research Site, Padua
Research Site, Dakahlia
Research Site, Verona
Research Site, Kisumu
Research Site, Siaya
Research Site, Al Sharkeya
Research Site, Barakaldo
Research Site, Oak Lawn
Research Site, Chicago
Research Site, Naples
Research Site, Las Vegas
Research Site, Catania
Research Site, Mumbai
Research Site, Pune
Research Site, Pune
Research Site, Nagpur
Research Site, Nagpur
Research Site, Wardha
Research Site, Porto Alegre
Research Site, Rio de Janeiro
Research Site, Salvador
Research Site, São Paulo
Research Site, São Paulo
Research Site, Nairobi
Research Site, Beirut
Research Site, Barcelona
Research Site, Seyhan
Research Site, Masaka
Research Site, Cardiff
Research Site, Glasgow
Research Site, London
Research Site, London
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
AstraZeneca
INDUSTRY